stockrowThe Chemours Company
CC Basic Materials Specialty Chemicals
The Chemours Company’s revenue for fiscal 2025 (year ended December 2025) was $5.8 billion, roughly unchanged from fiscal 2024.
- Revenue
- +3.01%
- EPS
- +223.8%
- Free cash flow
- −12.5%
- Total debt
- −7.64%
Quarter to September 2026, against a year earlier
Follow CC
Alert me
The Chemours Company (CC) EBITDA
The Chemours Company's EBITDA for fiscal 2025 was $287.0M, down 57.7% from $679.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $217.0M. Over the past ten years it has ranged from $73.0M (fiscal 2023) to $1.5B (fiscal 2018); the current reading is higher than 36% of that period. The Chemours Company ranks 31st of 59 Specialty Chemicals companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $287.0M | (57.73%) |
| FY2024 | $679.0M | 830.14% |
| FY2023 | $73.0M | (93.19%) |
| FY2022 | $1.1B | 6.99% |
| FY2021 | $1.0B | 43.97% |
| FY2020 | $696.0M | 4.19% |
| FY2019 | $668.0M | (54.80%) |
| FY2018 | $1.5B | 16.65% |
| FY2017 | $1.3B | 515.05% |
| FY2016 | $206.0M | 44.06% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$131.0M | — |
| Mar 2026 | $108.0M | 68.75% |
| Dec 2025 | $64.0M | (63.64%) |
| Sep 2025 | $176.0M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| FUL H. B. Fuller Company compare | $564.5M |
| KWR Quaker Houghton compare | $255.7M |
| NGVT Ingevity Corporation compare | $237.9M |
| CC The Chemours Company | $217.0M |
| IOSP Innospec Inc. compare | $184.5M |
| SCL Stepan Company compare | $149.2M |
| WDFC WD-40 Company compare | $119.3M |
| MTX Minerals Technologies Inc. compare | $73.0M |
| STDN Standard Nuclear Inc compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CC
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement